Dna X (SONM) Change in Accured Expenses (2018 - 2026)

Dna X has reported Change in Accured Expenses for 9 years, with the latest figure at -$1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 490.83% year-over-year to -$1.3 million; the trailing twelve-month figure through Mar 2026 stood at -$3.0 million (down 136.99% YoY), and the FY2025 full-year result was -$2.0 million, down 124.47% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.3 million, up from -$1.9 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $9.8 million in Q3 2024, with the low at -$2.8 million in Q4 2024.
• Historically, Change in Accured Expenses has averaged $338058.8 across 5 years, with a median of $81000.0 in 2022.
• The largest YoY upside for Change in Accured Expenses was 1886.42% in 2023 against a maximum downside of 778.1% in 2023.
• Dna X's Change in Accured Expenses stood at $81000.0 in 2022, then jumped by 1886.42% to $1.6 million in 2023, then slumped by 275.7% to -$2.8 million in 2024, then jumped by 31.66% to -$1.9 million in 2025, then jumped by 33.33% to -$1.3 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.3 million (Q1 2026), -$1.9 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.